This article is more than 5 years old. Information may no longer be current.

Read the top 7 EULAR articles about rheumatoid arthritis research

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Research presented at the European League Against Rheumatism Annual European Congress of Rheumatology, which took place between June 10 and 13 in Rome, focused heavily on rheumatoid arthritis. The editor of Healio.com/Rheumatology has assembled a collection of the most highly trafficked articles on the topic below.

Biosimilars were among the most popular topics in rheumatoid arthritis (RA), along with fatigue and the efficacy of several monoclonal antibody therapies at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology.

Similar immunogenicity profile between Remicade, biosimilar observed in patients with RA, AS

Patients with RA and ankylosing spondylitis (AS) responded with a similar immunogenicity profile to Remicade (infliximab, Janssen) and the Remicade biosimilar, Remsima (CT-P13, Celltrion), but other differences were observed between the two patient groups, according to researchers. Read more.

Efficacy similar for patients who switched from Remicade to Inflectra

Results presented at the EULAR Annual European Congress of Rheumatology showed that during the course of 11 months, patients experienced similar effectiveness after switching from Remicade (infliximab, Janssen) to the infliximab biosimilar, Inflectra (Hospira). Read more.

Risk of serious infection with non-biologic DMARD use tripled in patients with RA

Patients with RA treated with non-biologic disease-modifying anti-rheumatic drugs had three-times the risk for developing a serious infection compared with the general population, according to research by Elizabeth Arkema, ScD, and colleagues. Read more.

Fatigue, disease activity may predict rescue medication need in patients with RA receiving sarilumab

Disease activity and energy levels were predictive of the need for rescue medications in patients with rheumatoid arthritis who were treated with sarilumab compared with those treated with placebo, according to research presented at the EULAR Annual European Congress of Rheumatology. Read more.

Acthar Gel may be effective in nonresponding patients with RA

Patients with RA who failed to respond to prior treatment with biological agents with three different mechanisms of action may respond to treatment with Acthar Gel (repository corticotropin, Mallinckrodt), according to data from a presentation at the EULAR Congress. Read more.

Xeljanz monotherapy may improve symptoms of RA

Xeljanz (tofacitinib, Pfizer) prescribed alone may improve the symptoms of RA compared with methotrexate monotherapy, according to results from a phase 3 trial. Read more.

Improvement in health-related quality of life seen when sarilumab was added to treatment for RA

Many patients who received sarilumab in addition to methotrexate reported a better health-related quality of life compared with patients who received placebo and methotrexate, especially for bodily pain, vitality and fatigue, according to research presented at the EULAR Congress. Read more.